Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2009 - 2019)
Alnylam Pharmaceuticals' (ALNY) quarterly Change in Account Payables came in at -$30.1 million in Q3 2019, down 431.18% YoY from $9.1 million in Q3 2018, and down 169.16% on a QoQ basis from $43.5 million in Q2 2019.
Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2009 - 2019) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 11 years of Change in Account Payables data on file, last reported at -$30.1 million in Q3 2019.
- Quarterly Change in Account Payables fell 431.18% year-over-year to -$30.1 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $12.4 million (up 6.22% YoY) and the FY2018 annual result came in at $15.5 million, up 413.38% from the prior year.
- Change in Account Payables fell to -$30.1 million in Q3 2019, from $43.5 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $43.5 million in Q2 2019 to a low of -$30.1 million in Q3 2019.
- A 5-year average of $978631.6 and a median of $347000.0 in 2016 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2017 — Change in Account Payables plunged 3289.34% — and 2019, when it surged 6377.34%.
- Tracing ALNY's Change in Account Payables over 5 years: stood at $2.6 million in 2015, then soared by 351.39% to $11.6 million in 2016, then rose by 6.68% to $12.3 million in 2017, then soared by 30.78% to $16.1 million in 2018, then sank by 286.56% to -$30.1 million in 2019.
- The last three Change in Account Payables figures came in at -$30.1 million (Q3 2019), $43.5 million (Q2 2019), and -$17.1 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 7.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -30.09 Mn |
| Sep 30, 2019 | -30.09 Mn |
| Jun 30, 2019 | 43.50 Mn |
| Jun 30, 2019 | 43.50 Mn |
| Mar 31, 2019 | -17.13 Mn |
| Mar 31, 2019 | -17.13 Mn |
| Dec 31, 2018 | 16.13 Mn |
| Dec 31, 2018 | 16.13 Mn |
| Sep 30, 2018 | 9.09 Mn |
| Sep 30, 2018 | 9.09 Mn |
| Jun 30, 2018 | -693,000.00 |
| Jun 30, 2018 | -693,000.00 |
| Mar 31, 2018 | -9.04 Mn |
| Mar 31, 2018 | -9.04 Mn |
| Dec 31, 2017 | 12.33 Mn |
| Dec 31, 2017 | 12.33 Mn |
| Sep 30, 2017 | -8.95 Mn |
| Sep 30, 2017 | -8.95 Mn |
| Jun 30, 2017 | 2.74 Mn |
| Jun 30, 2017 | 2.74 Mn |